Qin Yajie, Yang Xiaotian, Zhao Qi, Tang Xingran, Zhao Huijin, Jiao Yang, Zhou Huifang
The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Medicine (Baltimore). 2024 Dec 6;103(49):e40528. doi: 10.1097/MD.0000000000040528.
Endometriosis (EMs) is a common chronic inflammatory gynecological disease that belongs to the classification of Traditional Chinese Medicine Syndromes "Zheng Jia," and the classic Chinese formula Guizhi Fuling (GZFL) demonstrates significant clinical efficacy in the treatment of this condition. This study aims to investigate GZFL's effect and potential mechanism in EMs.
The search reviewed randomized controlled trials in 7 databases from inception to 2024, assessed quality with the Cochrane tool, and analyzed data with STATA 15 by 2 reviewers. In the network pharmacology study, we searched and screened the components and targets of GZFL, subsequently compared these targets to EMs targets, and used bioinformatics techniques to analyze and explore their potential interactions.
Nine randomized controlled trials involving 897 participants were analyzed. Meta-analysis showed that GZFL combined with dienogest significantly enhanced the clinical effectiveness rate (odds ratio = 2.404, 95% confidence intervals [CI], 1.868 to 3.093; P < .001). Specifically, combination therapy with GZFL reduced serum carbohydrate antigen 125 (standardized mean differences [SMD] = -1.65, 95% CI = -2.13 to -1.17, P < .001), estradiol (SMD = -1.54, 95% CI = -1.89 to -1.19, P = .003), matrix metalloproteinases (SMD = -2.636, 95% CI = -2.993 to -2.279, P < .001), pain scores (SMD = -0.88, 95% CI = -1.11 to -0.67, P < .001) and the diameter of ectopic cysts (SMD = -1.7, 95% CI = -2.42 to -0.98, P < .001). Network pharmacology analysis identified 136 components and 145 common targets, focusing on interleukin-6, cellular tumor antigen p53, epidermal growth factor receptor, estrogen receptor alpha, Cyclooxygenase-2, and matrix metalloproteinases-9. Gene ontology and Kyoto Encyclopedia of Genes and Genomes analyses suggested GZFL modulates hormone receptors and inflammatory responses in EMs treatment.
In conclusion, GZFL combination treatment could increase the clinical effectiveness rate of EMs patients, and reduce the serum level of carbohydrate antigen 125, estradiol, matrix metalloproteinases, pain scores, and the diameter of the ectopic cyst. The potential mechanism might be linked to the modulation of hormone receptors and inflammation.
子宫内膜异位症(EMs)是一种常见的慢性炎症性妇科疾病,属于中医“症瘕”范畴,经典中药方剂桂枝茯苓(GZFL)在治疗该疾病方面显示出显著的临床疗效。本研究旨在探讨GZFL对EMs的作用及潜在机制。
检索7个数据库从建库至2024年的随机对照试验,使用Cochrane工具评估质量,由2名评价者用STATA 15分析数据。在网络药理学研究中,搜索并筛选GZFL的成分和靶点,随后将这些靶点与EMs靶点进行比较,并使用生物信息学技术分析和探索它们的潜在相互作用。
分析了9项涉及897名参与者的随机对照试验。荟萃分析表明,GZFL联合地诺孕素显著提高临床有效率(优势比=2.404,95%置信区间[CI],1.868至3.093;P<.001)。具体而言,GZFL联合治疗降低了血清糖类抗原125(标准化均数差[SMD]=-1.65,95%CI=-2.13至-1.17,P<.001)、雌二醇(SMD=-1.54,95%CI=-1.89至-1.19,P=.003)、基质金属蛋白酶(SMD=-2.636,95%CI=-2.993至-2.279,P<.001)、疼痛评分(SMD=-0.88,95%CI=-1.11至-0.67,P<.001)和异位囊肿直径(SMD=-1.7,95%CI=-2.42至-0.98,P<.001)。网络药理学分析确定了136种成分和145个共同靶点,主要集中在白细胞介素-6、细胞肿瘤抗原p53、表皮生长因子受体、雌激素受体α、环氧化酶-2和基质金属蛋白酶-9。基因本体论和京都基因与基因组百科全书分析表明,GZFL在EMs治疗中调节激素受体和炎症反应。
总之,GZFL联合治疗可提高EMs患者的临床有效率,降低血清糖类抗原125、雌二醇、基质金属蛋白酶水平、疼痛评分和异位囊肿直径。潜在机制可能与激素受体调节和炎症有关。